Why the study?
Does ethinyl estradiol improve lipid profiles in patients with type III hyperlipoproteinemia?
Does ethinyl estradiol improve lipid profiles in patients with type III hyperlipoproteinemia?
Ethinyl estradiol exerts a paradoxical hypolipidemic effect in patients with type III hyperlipoproteinemia, suggesting it facilitates the assimilation of chylomicron and VLDL remnants.
Answers are grounded in this paper and cite their sources.
Should not change practice in type III hyperlipoproteinemia; hypothesis-generating case observation requiring controlled trials.
Exogenous estrogens (ethinyl estradiol, 1 microgram/kg body weight per day), which stimulate triglyceride production in normal women and those with endogenous hypertriglyceridemia, were found to exert a paradoxical, hypolipidemic effect in six subjects (five women, one man) with type III hyperlipoproteinemia on diets both of normal and of fat-free, high-carbohydrate composition. Moreover, very low-density (VLD) lipoprotein lipid and apolipoprotein composition and electrophoretic mobility became normal during estrogen administration in these subjects. Levels of normal VLD lipoproteins remained mildly to moderately elevated in a type IV lipoprotein pattern. Estrogen withdrawal promptly restored the type III pattern with its abnormal enrichment of VLD lipoproteins with apolipoprotein E (the arginine-rich peptide). These findings suggest that estrogens facilitate the assimilation of chylomicron and VLD lipoprotein remnants, a defect that appears likely to represent the metabolic abnormality underlying type III hyperlipoproteinemia.
No takes yet. Share an insight, caveat, or question.
Rampratap S. Kushwaha (1977) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: